|
[1]WHO.Hepatitis B[R/OL].http://www.who.int/mediacemtre/factsheets/fs204/en.html
|
|
[2]GANEM D, PRINCE AM.Hepatitis B virus infection-natural history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.
|
|
[3]HOOFNAGLE JH.Reactivation of hepatitis B[J].Hepatology, 2009, 49 (Suppl 5) :s156-s165.
|
|
[4]PERRILLO RP, GISH R, FALCK-YTTER YT.American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148 (1) :221-244.
|
|
[5]RAN J, FENG P.Recurrence and aggravation of chronic hepatitis B caused by glucocorticoid and immunosuppressant:a clinical analysis of 7 cases[J].West China Med J, 2009, 24 (2) :419-421. (in Chinese) 冉静, 冯萍.糖皮质激素及免疫抑制剂致慢性乙肝复发和加重的7例临床分析[J].华西医学, 2009, 24 (2) :419-421.
|
|
[6]YEO W, ZEE B, ZHONG S, et al.Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy[J].Br J Cancer, 2004, 90 (7) :1306-1311.
|
|
[7]LAI C, YUEN M.Systemic corticosteroid and reactivation of chronic hepatitis B[J].Respirology, 2010, 15 (7) :1017-1018.
|
|
[8]LING WH, SOE PP, PANG AS, et al.Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours[J].Br J Cancer, 2013, 108 (10) :1931-1935.
|
|
[9]HSU CH, HSU HC, CHEN HL, et al.Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells.A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy[J].Anticancer Res, 2004, 24 (5A) :3035-3040.
|
|
[10]WILCOX RA.Cutaneous B-cell lymphomas:2016 update on diagnosis, risk-stratification, and management[J].Am J Hematol, 2016, 91 (10) :1052-1055.
|
|
[11]DONG HJ, NI LN, SHENG GF, et al.Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy:a meta-analysis[J].J Clin Virol, 2013, 57 (3) :209-214.
|
|
[12]KIM SJ, HSU C, SONG YQ, et al.Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab:analysis from the Asia Lymphoma Study Group[J].Eur J Cancer, 2013, 49 (16) :3486-3496.
|
|
[13]EVENS AM, JOVANOVIC BD, SU YC, et al.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases:meta-analysis and examination of FDA safety reports[J].Ann Oncol, 2011, 22 (5) :1170-1180.
|
|
[14]YEO W, CHAN TC, LEUNG NW, et al.Hepatitis B Virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J].J Clin Oncol, 2008, 27 (4) :605-611.
|
|
[15]REDDY KR, BEAVERS KL, HAMMOND SP, et al.American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148 (1) :215-219.
|
|
[16]PREZ-ALVAREZ R, DAZ-LAGARES C, GARCA-HERNNDEZ F, et al.Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF) -targeted therapy[J].Medicine, 2011, 90 (6) :359-371.
|
|
[17]SHERON N, LAU J, DANIELS H, et al.Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection[J].J Hepatol, 1991, 12 (2) :241-245.
|
|
[18]MARINOS G, NAOUMOV NV, ROSSOL S, et al.Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection[J].Gastroenterology, 1995, 108 (5) :1453-1463.
|
|
[19]GUIDOTTI LG, CHISARI FV.Noncytolytic control of viral infections by the innate and adaptive immune response[J].Annu Rev Immunol, 2001, 19 (1) :65-91.
|
|
[20]HERBEIN G, O'BRIEN WA.Tumor necrosis factor (TNF) -alpha and TNF receptors in viral pathogenesis[J].Proc Soc Exp Biol Med, 2000, 223 (3) :241-257.
|
|
[21]GUIDOTTI LG, ISHIKAWA T, HOBBS MV, et al.Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes[J].Immunity, 1996, 4 (1) :25-36.
|
|
[22]WEAVER AL.Differentiating the new rheumatoid arthritis biologic therapies[J].J Clin Rheumatol, 2003, 9 (2) :99-114.
|
|
[23]CARROLL MB, FORGIONE MA.Use of tumor necrosis factor-αinhibitors in hepatitis B surface antigen-positive patients:a literature review and potential mechanisms of action[J].Clin Rheumatol, 2010, 29 (9) :1021-1029.
|
|
[24]AKASHI K, SAEGUSA J, NAKAMACHI Y, et al.Hepatitis B virus reactivation following salazosulfapyridine monotherapy in a patient with rheumatoid arthritis[J].Intern Med, 2016, 55 (10) :1371-1373.
|
|
[25]TALOTTA R, ATZENI F, SARZI PUTTINI P.Reactivation of occult hepatitis B virus infection under treatment with abatacept:a case report[J].BMC Pharmacol Toxicol, 2016, 17 (1) :17.
|
|
[26]PARK SK, YANG WS, LEE YS, et al.Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine[J].Nephrol Dial Transplant, 2001, 16 (11) :2222-2228.
|
|
[27]CHEN GD, GU JL, QIU J, et al.Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers[J].Transpl Infect Dis, 2013, 15 (3) :300-305.
|
|
[28]DEHGHANI SM, TAGHAVI SA, GERAMIZADEH B, et al.Hepatitis B recurrence after liver transplantation:a single center experiences and review the literature[J].Hepat Mon, 2013, 13 (1) :e6609.
|
|
[29]MIKULSKA M, NICOLINI L, SIGNORI A, et al.Hepatitis B reactivation in HBs Ag-negative/HBc Ab-positive allogeneic haematopoietic stem cell transplant recipients:risk factors and outcome[J].Clin Microbiol Infect, 2014, 20 (10) :694-701.
|
|
[30]KOWAZAKI Y, OSAWA Y, IMAMURA J, et al.Immunological analysis of a patient with hepatitis B virus (HBV) reactivation after bone marrow transplantation[J].Intern Med, 2015, 54 (10) :1213-1217.
|
|
[31]LIU LG, SHAO YL.Antiviral therapy in patients coinfected with hepatitis B virus and human immunodeficiency virus[J].World Chin J Dig, 2011, 19 (15) :1609-1613. (in Chinese) 柳龙根, 邵幼林.HBV/HIV重叠感染的抗病毒治疗[J].世界华人消化杂志, 2011, 19 (15) :1609-1613.
|
|
[32]GMEZ-GONZALO M, CARRETERO M, RULLAS J, et al.The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals:functional roles of NF-kappa B/NF-AT and SP1-binding sites in the HIV-1long terminal repeat promoter[J].J Biol Chem, 2001, 276 (38) :35435-35443.
|
|
[33]MU Y, YU Y, YUE X, et al.The X protein of HBV induces HIV-1 long terminal repeat transcription by enhancing the binding of C/EBPβand CREB1/2 regulatory proteins to the long terminal repeat of HIV-1[J].Virus Res, 2011, 156 (1-2) :81-90.
|
|
[34]LI YJ, WANG HL, LI TS.Hepatitis B virus/human immunodeficiency virus coinfection:interaction among human immunodeficiency virus infection, chronic hepatitis B virus infection, and host immunity[J].Chin Med J (Engl) , 2012, 125 (13) :2371-2377.
|
|
[35]RAIMONDO G, BRUNETTO MR, PONTISSO P, et al.Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients[J].Hepatology, 2006, 43 (1) :100-107.
|
|
[36]DONG B, ZHANG PP, ZHAO PD, et al.A case of acute coinfection with HBV and HCV[J].J Clin Hepatol, 2016, 32 (8) :1580-1581. (in Chinese) 东冰, 张萍萍, 赵培东, 等.急性HBV/HCV重叠感染1例报告[J].临床肝胆病杂志, 2016, 32 (8) :1580-1581.
|
|
[37]SHIH CM, LO SJ, MIYAMURA T, et al.Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in Hu H-7 cells[J].J Virol, 1993, 67 (10) :5823-5832.
|
|
[38]SCHUTTLER CG, FIEDLER N, SCHMIDT K, et al.Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein[J].J Hepatol, 2002, 37 (6) :855-862.
|
|
[39]POTTHOFF A, WEDEMEYER H, BOECHER WO, et al.The HEP-NET B/C co-infection trial:a prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection[J].J Hepatol, 2008, 49 (5) :688-694.
|
|
[40]LIU PH, RAO HY.Related immune manifestations in patients with chronic hepatitis B virus and chronic hepatitis C virus infection[J].J Clin Hepatol, 2016, 32 (10) :1870-1873. (in Chinese) 刘佩浩, 饶慧瑛.慢性HBV/HCV感染人群伴随的免疫相关表现[J].临床肝胆病杂志, 2016, 32 (10) :1870-1873.
|
|
[41]de MONTE A, COURJON J, ANTY R, et al.Direct-acting antiviral treatment in adults infected with hepatitis C virus:reactivation of hepatitis B virus coinfection as a further challenge[J].J Clin Virol, 2016, 78:27-30.
|
|
[42]SULKOWSKI MS, CHUANG WL, KAO JH, et al.No evidence of reactivation of hepatitis B virus among patients treated with ledipasvirsofosbuvir for hepatitis C virus infection[J].Clin Infect Dis, 2016, 63 (9) :ciw507.
|
|
[43]RAIMONDO G, ALLAIN JP, BRUNETTO MR, et al.Statements from the Taormina expert meeting on occult hepatitis B virus infection[J].J Hepatol, 2008, 49 (4) :652-657.
|
|
[44]LOOMBA R, ROWLEY A, WESLEY R, et al.Systematic review:the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J].Ann Intern Med, 2008, 148 (7) :519-528.
|
|
[45]CHENG AL, HSIUNG CA, SU IJ, et al.Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBVcarriers with lymphoma[J].Hepatology, 2003, 37 (6) :1320-1328.
|
|
[46]PERRILLO RP.Acute flares in chronic hepatitis B:the natural and unnatural history of an immunologically mediated liver disease[J].Gastroenterology, 2001, 120 (4) :1009-1022.
|
|
[47]YANG PL, ALTHAGE A, CHUNG J, et al.Immune effectors required for hepatitis B virus clearance[J].Proc Natl Acad Sci U S A, 2010, 107 (2) :798-802.
|
|
[48]YEO W.Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy[J].J Clin Oncol, 2004, 22 (5) :927-934.
|
|
[49]SETO WK, WONG DH, CHAN TY, et al.Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy[J].Am J Gastroenterol, 2016, 111 (12) :1788-1795.
|
|
[50]WI CI, LOO NM, LARSON JJ, et al.Low level of hepatitis B virus screening among patients receiving chemotherapy[J].Clin Gastroenterol Hepatol, 2015, 13 (5) :970-975.
|
|
[51]TRAN TT, RAKOSKI MO, MARTIN P, et al.Screening for hepatitis B in chemotherapy patients:survey of current oncology practices[J].Aliment Pharmacol Ther, 2010, 31 (2) :240-246.
|
|
[52]LEE RS, BELL CM, SINGH JM, et al.Hepatitis B screening before chemotherapy:a survey of practitioners'knowledge, beliefs, and screening practices[J].J Oncol Pract, 2012, 8 (6) :325-328.
|
|
[53]DAY FL, LINK E, THURSKY K, et al.Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors:a nationwide survey of medical oncologists[J].J Oncol Pract, 2011, 7 (3) :141-147.
|
|
[54]STINE JG, KHOKHAR OS, CHARALAMBOPOULOS J, et al.Rheumatologists'awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy[J].Arthritis Care Res (Hoboken) , 2010, 62 (5) :704-711.
|
|
[55]STINE JG, BASS M, IBRAHIM D, et al.Dermatologists awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-αinhibitor therapy[J].South Med J, 2011, 104 (12) :781-788.
|
|
[56]NGUYEN GC, SMALLEY WE, VEGE SS, et al.American gastroenterological association institute guideline on the medical management of microscopic colitis[J].Gastroenterology, 2016, 150 (1) :242-246.
|
|
[57]ZIAKAS PD, KARSALIAKOS P, MYLONAKIS E.Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma:a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance[J].Haematologica, 2009, 94 (7) :998-1005.
|
|
[58]HUANG YH, HSIAO LT, HONG YC, et al.Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B[J].J Clin Oncol, 2013, 31 (22) :2765-2772.
|
|
[59]HUANG H, LI X, ZHU J, et al.Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy[J].JAMA, 2014, 312 (23) :2521.
|
DownLoad: